• Skip to main content
BC

biochimica clinica

en_US English
en_US English it_IT Italian
  • Home
  • Casi clinici
  • Ahead of print e Ultimo Fascicolo - Accedi per visualizzare gli articoli
  • Archivio BC fino a 2024
  • Sottometti un articolo
  • Norme Autori
  • Cerca

RASSEGNE - Reviews

Volume:

Biochimica Clinica 2014; 38(1) 12-17

Pubblicato on-line:

DOI:

Scarica in PDF:
Autenticazione richiesta

Cistinuria

AUTORI

Maria Sole Cigoli1, Francesca Avemaria1, Silvana Penco1, Andrea Mosca2
1Genetica Medica, Ospedale Niguarda Cà Granda, Milano
2Centro Interdipartimentale per la Riferibilità Metrologica in Medicina di Laboratorio (CIRME), Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano

ABSTRACT

Cystinuria

Cystinuria is a rare inherited disorder, generally transmitted as an autosomal recessive trait. It is characterized by defective resorption (for deficits of transporter proteins) of cystine and dibasic amino acids at the level of renal proximal tubules and, to a lesser extent, of intestinal cells. The low solubility of cystine at physiologic urinary acidity leads to its precipitation in the form of crystals and stones, causing the urinary tract obstruction. The two genes responsible for cystinuria are SLC3A1 (chromosome 2p21) and SLC7A9 (chromosome 19q12), encoding for the heavy subunit rBAT and the light subunit b0,+AT of the renal b0,+ transporter, respectively. Cystinuria can be classified in type I and non-type I on the basis of urinary excretion rate of cystine. Alternatively, cystinuria can be classified as type A (SLC3A1 gene mutated), type B (SLC7A9 gene mutated) and type AB (mutations on both genes). Clinical symptoms and positivity of laboratory tests are the basis for diagnosis. Detection of mutations in SLC3A1 and SLC7A9 genes can be used to confirm the diagnosis and to identify possible carriers within the patient family. Although many advances have been made in the understanding of genetic and physiologic basis of cystinuria, the treatment still involves prevention of stone formation by dietary measures and drug therapy coupled with surgical intervention for stone removal.

BIBLIOGRAFIA

HOME
PRIVACY POLICY
5x1000 Docemus

LOGO SIBioC

EDITORE RESPONSABILE
Alberto Oliaro

EDITORIAL SECRETARY
Edizioni Minerva Medica S.p.A.
Corso Bramante 83-85, 10126 Torino
T +39 011 678282
journals.dept@minervamedica.it

Designed by Biomedia srl
© 2025 SIBioC
P. IVA IT 06484860967